NASH in 2021: The Multi-system Disease


22nd Jun 2021



Sponsored by:

Date: June 22, 2021 (Tuesday)
Time: San Francisco 7:30 AM| New York 11:30 AM | London 4:30 PM | Paris 5:30 PM| Singapore 11:30 PM | Tokyo 00:30 AM (June 23) | Sydney 1:30 AM (June 23) 
Duration: 90 minutes
Registration fee: Complimentary access
Webinar on-demand: Available to view until midnight July 9, 2021 (registration is required)

Non-alcoholic steatohepatitis (NASH) is a major unmet health need and currently a significant, growing worldwide cause of chronic liver disease with an ever-increasing toll on cirrhotic morbidity, hepatocellular carcinoma and liver transplantation. Predisposing conditions such as adipose tissue insulin resistance, adipocytokine imbalance and systemic inflammation promote hepatic lipotoxicity, leading to inflammatory and fibrotic liver injury.

NASH is a multi-system disease with cardiovascular complications, worsening of metabolic dysfunction and other extra-hepatic diseases, such as type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), or certain extra-hepatic cancers.

Both the management and treatment of NASH require a holistic approach. Peroxisome proliferator-activated receptors (PPARs) have been shown to have a role in several and complementary physiological processes including carbohydrate and lipid metabolism as well as inflammation and fibrogenesis, and represent a promising target for therapy. Ongoing clinical trials suggest that dual and especially pan-PPAR agonists might have a broader and more efficient therapeutic potential to affect the multisystem disease of NASH by targeting different interrelated mechanisms in its pathophysiology.

This Pan NASH interactive webinar will discuss these important scientific issues with a global and interdisciplinary perspective.

Educational objectives:

• Review the latest epidemiological data about NAFLD and NASH, and how the burden of the disease extends beyond liver manifestations.
• Understand the pathogenesis and natural course of NAFL and NASH, and the rational for addressing NAFLD and NASH as part of a multisystem disease.
• Discuss the relationship between NASH and the risk of developing cardiovascular diseases, aggravating insulino-resistance and other extra-hepatic diseases.
• Evaluate the latest research options for the treatment of NASH and their potential implications for clinical practice.


Webinar Agenda:

Time (CET) Agenda Speaker
17:00 – 17:10 Welcome and Introduction to the webinar S. Francque
17:10 – 17:20 NASH overview in 2021 A. Sanyal
17:20 – 17:30 NASH and CV system and risks C. Byrne
17:30 – 17:40 NASH and hepatic vascularization J. Gracia
17:40 – 17:50 NASH and insulin resistance (and CV consequences) K. Cusi
17:50 – 18:00 Current progress and future promise: the therapeutic approaches  M. Abdelmalek
18:00 – 18:20 Q&A All
18:20 – 18:30 Conclusion and take-home messages S. Francque


Sven Francque (Moderator)
Chairman of the Department of Gastroenterology and Hepatology, University Hospital Antwerp
Prof. Sven Francque, MD, has a long-standing interest and expertise in non-alcoholic fatty liver disease and conducted basic research focusing on the vascular changes in steatosis and their contribution to disease progression. His research unit continues to study pathophysiological mechanisms of NASH. He participates in several key clinical trials in the field.
Presentation Topic: Welcome and Introduction to the webinar
• Epidemiology, patients’ profiles and predisposing conditions for NASH

Arun Sanyal
Z Reno Vlahcevic Professor of Medicine, Virginia Commonwealth University School of Medicine
Prof. Arun J. Sanyal is the Reno Vlahcevic Professor of Medicine at VCU School of Medicine. He has over 30 years of experience as a leading physician-scientist and undertakes academic research in two major areas of hepatology: cirrhosis and its complications, and alcoholic/nonalcoholic steatohepatitis.
Presentation Topic: NASH overview in 2021
• NASH pathophysiology; diagnosis issue (liver biopsy, non-invasive biomarkers etc) and prognostication
• Natural history of NASH: steatosis, inflammation, fibrosis, cirrhosis … with inflammation as progression paramount

Chris Byrne
Professor Endocrinology & Metabolism, University Hospital Southampton
Prof. Byrne is a leader in metabolic medicine with a research focus on diabetes and non-alcoholic fatty liver disease (NAFLD). His research spans epidemiology, basic mechanisms and innovative clinical trials. He took a strong translational direction and he was selected as a NICE expert.
Presentation Topic : NASH and CV system and risks
• NASH and atherogenic dyslipidaemia

Jordi Gracia-Sancho
Chief of the Liver Vascular Biology Research Group, IDIBAPS Research Institute – Hospital Clínic de Barcelona and Department of Biomedical Research – University of Bern
Dr. Gracia’s research focuses on liver vascular pathobiology with special interest in the role of sinusoidal cells, and their interactions, in acute and chronic liver diseases, and in aging. In 2016 he received the Emerging Leader Award from European Association for the Study of the Liver (EASL).
Presentation Topic: NASH and hepatic vascularization
• Hepatic vascularization
• Therapeutic implications

Kenneth Cusi
Chief, Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville
Prof. Cusi has a longstanding interest in the relationship and underlying mechanisms of nonalcoholic fatty liver disease (NAFLD) in Type 2 diabetes mellitus (T2DM and its impact on dyslipidemia, diabetes control and cardiovascular disease). He is the principal investigator of various ongoing clinical translational research projects in obesity, T2DM and NAFLD.
Presentation Topic: NASH and insulin resistance (and CV consequences)
• Dysregulated glucose and lipid metabolism
• NASH / T2DM interdependence

Manal F. Abdelmalek
Professor of Medicine, Division of Gastroenterology & Hepatology, Duke University
Dr Abdelmalek is the Director of the NAFLD Clinical Research Program at Duke University. Since first reporting NASH as a case of cryptogenic cirrhosis over 20 years ago, her research area of interest has focused on risk factors for NAFLD acquisition, fibrosis progression, and discovery of new and novel therapeutic interventions.
Presentation Topic: Current progress and future promise: the therapeutic approaches
• Main learning in 2020
• Clinical studies’ state-of-the-art (end-points, NASH resolution and hepatic fibrosis improvement)
• Clinically-demonstrated benefits of PPARs (histology, biology, clinically, …)
• The implications in clinical practice


PanNASH™ initiative, a working group consisting of a committee of international independent experts that aims to increase the visibility and contribute to a better understanding of NASH (a multisystem disease), to share their expertise and to establish best practices for the treatment of the disease has been supported since three years by Inventiva S.A. a biopharmaceutical company developing innovative therapies in nonalcoholic steatohepatitis (NASH), systemic sclerosis (SSc) and mucopolysaccharidosis (MPS).

The committee, which is entirely funded by Inventiva, includes European, American and Asian medical experts in areas related to NASH such as hepatology, diabetes and cardiology, along with renowned scientific experts focused on promoting a better understanding of the physiopathological mechanisms involved in NASH (see the list of the founding members in PanNASH initiative web site – Their aim will therefore be to play an active role in developing and disseminating their NASH expertise among the scientific community, patients and other key stakeholders within the healthcare system.

In particular, the experts group intends to help develop and share new findings about NASH through scientific publications, conferences and training sessions. It will particularly focus on the development of the disease as a multi-system disease, the identification of patients at risk, clinical markers and associated health risks, as well as the development of new treatments. Specifically, the committee will help to increase knowledge of pathological mechanisms ranging from metabolic disorders to fibrosis and comorbidities, with a focus on the modulating role played by PPARs (peroxisome proliferator-activated receptors, α, δ, ɣ subtypes).

Interested in hosting your own webinar or online panel discussion?

With over a decade of experience in hosting life science events, Global Engage is your ideal partner to either devise an agenda for you or work with you and your speakers to promote the online event to our extensive databases.

Contact us to discuss how we can make a webinar / online panel discussion work for you

For further details please contact
Gavin Hambrook
Telephone +44 (0) 7538 368 764 or
email [email protected]

Reuben Raj
Telephone: +603 2117 5193 or
email [email protected]


The meeting is free to attend
Register today